drugset / Trial / NCT06193148

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

NCT06193148

Phase 1 Completed 32 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effect of Jaktinib Hydrochloride Tablets on QT/QTc interval in healthy subjects after a single oral administration.

Timeline

Start
2024-03-19
Primary completion
2024-06-18
Completion
2024-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 100 mg Oral
Subject Jaktinib Unknown 400 mg Oral
Subject Jaktinib Unknown 600 mg Oral
Subject Jaktinib Unknown 800 mg Oral

Indications

No indication recorded.